Portfolio
Unleashing Opportunities
Uncover Value
Tech & Digital Investee
Our core technology is an encryption key management system that ensures the security of digital assets, data encryption, and access control. It is widely applied in the blockchain industry. In 2022, it was acquired by the financial technology company Circle.
Our mission is to deliver our customers the next generation of IT storage infrastructure for NVMe and NVMeoF SSDs, without sacrificing the performance they need. SupremeRAID™ revolutionary GPU-based RAID delivers the speed, ease of use, flexibility and TCO the market demands for the future of high-performance workloads.
As a leading provider of 3D industrial sensors, we specialize in parallel structured light sensing technology combined with high-precision robotics and AI software. We offer comprehensive industrial solutions to meet diverse needs.
Bio & Medical Investee
BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech business veteran, Y. Peter Li, Ph.D., M.B.A. BlossomHill Therapeutics, Inc. is headquartered in San Diego, California.
ClearMind provides a better and efficient way to treat intracerebral hemorrahge (ICH). ClearMind works with neurosurgeons to formulate ICH solutions. A best solution with minimal invasiveness, less operation time and better neurological recovery.
Renxin Pharmaceuticals’ LBS-008 has obtained orphan drug designation from the U.S. FDA, pediatric rare disease designation, fast track designation, and orphan drug designation from the European Medicines Agency (EMA). In the 18-month interim analysis of the phase 2 clinical trial for adolescent Stargardt disease, the average vision has remained stable. Renxin Pharmaceuticals is poised to become the only company conducting a phase 3 clinical trial for Stargardt disease globally.
